Skip to content

Study · Randomized controlled trial · n = 41 · 2024

5 results

Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes.

Chowdhary A, Thirunavukarasu S, Joseph T, Jex N, Kotha S, Giannoudi M, Procter H, Cash L, Akkaya S, Broadbent D, Xue H, Swoboda P and 7 more

Show all authors

Valkovič L, Kellman P, Plein S, Rider OJ, Neubauer S, Greenwood JP, Levelt E

Journal of the American College of Cardiology1 Aug 2024Cited by 27 (Europe PMC)

PMID39084829 (opens in a new tab)PMCIDPMC11296502 (opens in a new tab)DOI10.1016/j.jacc.2024.04.064 (opens in a new tab)PepBankPUB-39084829
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 16 weeks of liraglutide increased stress myocardial blood flow.

    In plain wordsIn adults with type 2 diabetes, liraglutide raised heart muscle blood flow under stress after 16 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseStress myocardial blood flow
    Study

    n = 41

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Stress myocardial blood flow
    1.62 mL/g/min
    before liraglutide
    Stress myocardial blood flow
    2.08 mL/g/min
    after liraglutide

    Source sentences

    Summary
    Liraglutide treatment increased stress myocardial blood flow (1.62 mL/g/min [95% CI: 1.19-1.75 mL/g/min] to 2.08 mL/g/min [95% CI: 1.57-2.24 mL/g/min]; P = 0.01)
    1 context sentence
    Summary · context
    Forty-one patients with T2D (age 63 years [95% CI: 59-68 years], 27 [66%] male, body mass index 27.8 kg/m2) [95% CI: 26.1-29.5 kg/m2)]) without cardiovascular disease were randomized to liraglutide or pioglitazone for a 16-week treatment followed by an 8-week washout and a furt…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 16 weeks of liraglutide increased myocardial perfusion reserve.

    In plain wordsIn adults with type 2 diabetes, liraglutide improved the heart muscle's blood flow reserve after 16 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseMyocardial perfusion reserve
    Study

    n = 41

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Myocardial perfusion reserve
    2.4 ratio
    before liraglutide
    Myocardial perfusion reserve
    2.9 ratio
    after liraglutide

    Source sentences

    Summary
    myocardial perfusion reserve (2.40 [95% CI: 1.55-2.68] to 2.90 [95% CI: 1.83-3.18]; P = 0.01).
    1 context sentence
    Summary · context
    Forty-one patients with T2D (age 63 years [95% CI: 59-68 years], 27 [66%] male, body mass index 27.8 kg/m2) [95% CI: 26.1-29.5 kg/m2)]) without cardiovascular disease were randomized to liraglutide or pioglitazone for a 16-week treatment followed by an 8-week washout and a furt…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 16 weeks of liraglutide increased the resting myocardial phosphocreatine to ATP ratio.

    In plain wordsIn adults with type 2 diabetes, liraglutide raised a heart energy marker at rest after 16 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseRest phosphocreatine to ATP ratio
    Study

    n = 41

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Rest PCr/ATP ratio
    1.47 ratio
    before liraglutide
    Rest PCr/ATP ratio
    1.94 ratio
    after liraglutide

    Source sentences

    Summary
    Liraglutide treatment also significantly increased the rest (1.47 [95% CI: 1.17-1.58] to 1.94 [95% CI: 1.52-2.08]; P =0.00002)
    1 context sentence
    Summary · context
    Forty-one patients with T2D (age 63 years [95% CI: 59-68 years], 27 [66%] male, body mass index 27.8 kg/m2) [95% CI: 26.1-29.5 kg/m2)]) without cardiovascular disease were randomized to liraglutide or pioglitazone for a 16-week treatment followed by an 8-week washout and a furt…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 16 weeks of liraglutide increased the myocardial phosphocreatine to ATP ratio under stress.

    In plain wordsIn adults with type 2 diabetes, liraglutide raised a heart energy marker under stress after 16 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseStress phosphocreatine to ATP ratio
    Study

    n = 41

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    Stress PCr/ATP ratio
    1.32 ratio
    before liraglutide
    Stress PCr/ATP ratio
    1.58 ratio
    after liraglutide

    Source sentences

    Summary
    and stress phosphocreatine to adenosine triphosphate ratio (1.32 [95% CI: 1.05-1.42] to 1.58 [95% CI: 1.19-1.71]; P = 0.004)
    1 context sentence
    Summary · context
    Forty-one patients with T2D (age 63 years [95% CI: 59-68 years], 27 [66%] male, body mass index 27.8 kg/m2) [95% CI: 26.1-29.5 kg/m2)]) without cardiovascular disease were randomized to liraglutide or pioglitazone for a 16-week treatment followed by an 8-week washout and a furt…
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, 16 weeks of liraglutide increased 6-minute walk distance.

    In plain wordsIn adults with type 2 diabetes, liraglutide increased the distance walked in 6 minutes after 16 weeks.

    Peptide
    Liraglutide
    Outcome
    Increase6-minute walk distance
    Study

    n = 41

    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    Dose not stated · 16 weeksAs given in this study (human).

    Measurements

    6-minute walk distance
    488 m
    before liraglutide
    6-minute walk distance
    521 m
    after liraglutide

    Source sentences

    Summary
    6-minute walk distance (488 m [95% CI: 458-518 m] to 521 m [95% CI: 481-561 m]; P = 0.009).
    1 context sentence
    Summary · context
    Forty-one patients with T2D (age 63 years [95% CI: 59-68 years], 27 [66%] male, body mass index 27.8 kg/m2) [95% CI: 26.1-29.5 kg/m2)]) without cardiovascular disease were randomized to liraglutide or pioglitazone for a 16-week treatment followed by an 8-week washout and a furt…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT04657939

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

University of Leedsn = 571 Dec 2020 to 31 Oct 2022

Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 27 Feb 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.